Our mission is to advance new therapies for people living with epilepsy. More than a third of the 3 million epilepsy patients in the United States have persistent seizures using existing therapies. Many others tolerate serious side effects, including diminished cognition, as a price for seizure control. New therapies introduced over the last decade offer fewer side effects but have done little to bring effective seizure control to the significant population living with active and uncontrolled epilepsy. Despite this serious unmet medical need, research funding for epilepsy is scarce and existing philanthropic support limited. Further, many major pharmaceutical companies have scaled back epilepsy development programs. As a result, successful lab research and new findings are rarely translated into new epilepsy therapy.